公开(公告)号：US20240165226A1

公开(公告)日：2024-05-23

申请号：US18488634

申请日：2023-10-17

Applicant: GENMAB A/S

Inventor： Jan VAN DE WINKEL ,  Paul PARREN ,  Yvo GRAUS ,  Judith OPRINS ,  Michel DE WEERS ,  Martine VAN VUGT ,  Ole BAADSGAARD ,  Steen LISBY

IPC: A61K39/395 ,  A61K31/198 ,  A61K31/4439 ,  A61K31/573 ,  A61K31/69 ,  A61K45/06 ,  A61P19/02 ,  A61P35/00 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K31/198 ,  A61K31/4439 ,  A61K31/573 ,  A61K31/69 ,  A61K39/39558 ,  A61K45/06 ,  A61P19/02 ,  A61P35/00 ,  C07K16/2896 ,  A61K2039/505 ,  C07K2317/34

Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.

公开(公告)号：US20240091352A1

公开(公告)日：2024-03-21

申请号：US18175894

申请日：2023-02-28

Applicant: GENMAB A/S

Inventor： Esther BREIJ ,  David SATIJN ,  Edward Norbert VAN DEN BRINK ,  Dennis VERZIJL ,  Rob N. DE JONG ,  Paul PARREN ,  Riemke VAN DIJKHUIZEN RADERSMA

IPC: A61K39/395 ,  A61K47/68 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K47/6801 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  C07K16/2863 ,  C07K16/3061 ,  A61K2039/505

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US20230257479A1

公开(公告)日：2023-08-17

申请号：US17642488

申请日：2020-09-11

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C.W. BREIJ ,  Bart E.C.G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN ,  Reshma Abdulla RANGWALA ,  Sri GHATTA ,  Ruud BRAKENHOFF ,  Rieneke VAN DE VEN

IPC: C07K16/30 ,  A61P35/00 ,  A61P1/00

CPC classification number: C07K16/30 ,  A61P1/00 ,  A61P35/00 ,  A61K2039/505

Abstract: The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).

公开(公告)号：US20230089969A1

公开(公告)日：2023-03-23

申请号：US17817033

申请日：2022-08-03

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20230087745A1

公开(公告)日：2023-03-23

申请号：US17821837

申请日：2022-08-24

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Ugur SAHIN ,  Friederike GIESEKE ,  Alexander MUIK ,  Christian GRUNWITZ ,  Edward VAN DEN BRINK ,  Dennis VERZIJL

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20230076417A1

公开(公告)日：2023-03-09

申请号：US17714735

申请日：2022-04-06

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Joost MELIS ,  Tom VINK ,  Hendrik TEN NAPEL ,  Esther BREIJ ,  David SATIJN ,  Paul PARREN

IPC: C07K16/32 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28

Abstract: The present invention relates to a multispecific antigen-binding molecule comprising a first antigen-binding domain and a second antigen-binding domain. The first domain specifically binds a target molecule (T), and the second domain specifically binds an internalizing effector protein (E), the second antigen-binding domain having a dissociation constant (KD) with E of between 10−9 and 10−8 M. The multispecific antigen-binding molecule is useful in a method for treating and/or preventing a cancer.

公开(公告)号：US20220177585A1

公开(公告)日：2022-06-09

申请号：US17349482

申请日：2021-06-16

Applicant: GENMAB A/S

Inventor： Catharina Emanuele GERARDA HAVENITH ,  Tom VINK ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: C07K16/28 ,  G01N33/566

Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.

公开(公告)号：US20220169738A1

公开(公告)日：2022-06-02

申请号：US17369542

申请日：2021-07-07

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD ,  Jan VAN DE WINKEL ,  David SATIJN ,  Paul PARREN ,  Aran Frank LABRIJN ,  Joyce MEESTERS ,  Janine SCHUURMAN ,  Edward N. VAN DEN BRINK

IPC: C07K16/28 ,  C07K16/32

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20220033510A1

公开(公告)日：2022-02-03

申请号：US17360438

申请日：2021-06-28

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20210369842A1

公开(公告)日：2021-12-02

申请号：US17289602

申请日：2019-11-06

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Ugur SAHIN ,  Friederike GIESEKE ,  Alexander MUIK

IPC: A61K39/395 ,  C07K16/28 ,  A61P35/00 ,  A61K47/22 ,  A61K47/26 ,  A61K9/00

Abstract: The present invention relates to pharmaceutical formulations of binding agents and their use in medicine. In particular, the invention relates to pharmaceutical formulations of binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the pharmaceutical formulations of the invention and to methods for producing pharmaceutical formulations.